U
ICPT

UBS’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

UBS’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$71K Sell
300
-8,300
-97% -$2.12M ﹤0.01% 6407
2014
Q2 		$2.04M Buy
8,600
+4,400
+105% +$1.16M ﹤0.01% 2860
2014
Q1 		$1.39M Buy
+4,200
New +$1.42M ﹤0.01% 3141

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS's ICPT Position: Q3 2014 in Review

UBS reduced its Intercept Pharmaceuticals, Inc. (ICPT) stake by 52% in Q3 2014, selling an estimated $2.47M and leaving 8,835 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

UBS first reported a position in ICPT in Q3 2013 and has held it in 5 quarters since. The position peaked at $4.38M in Q2 2014. 181 funds tracked by Wall St. Rank hold ICPT as of Q3 2014.

  • UBS held 8,835 shares of Intercept Pharmaceuticals, Inc. worth $2.09M as of Q3 2014.
  • UBS sold 9,677 Intercept Pharmaceuticals, Inc. shares in Q3 2014, an estimated $2.47M.
  • Intercept Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2874 holding.
  • UBS first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and has held it in 5 quarters since.
  • UBS's Intercept Pharmaceuticals, Inc. position peaked at $4.38M in Q2 2014.
  • 181 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.